Double Chiral Switches in ADHD Medication Reveal Hidden Complexity

Strategic Insights -

Researchers at Sapienza University of Rome have shed new light on the development of Attention Deficit Hyperactivity Disorder (ADHD) medications, particularly in the case of methylphenidate. The study reveals the strategic incorporation of double chiral switches in these medications, which has led to the development of successful ADHD treatments such as Ritalin and Focalin. However, the research also highlights the inaccuracies in the notations of the active ingredients of these medications.

Key Takeaways:

  • The study presents the strategy of double chiral switches of drugs, specifically illustrating the scenario of consecutive double chiral switches of methylphenidate.
  • The two chirality centers of methylphenidate hydrochloride give rise to four stereoisomers grouped into two racemates, two enantiomer pairs: [(a,2)/(a,2)] (racemate a) and [(a,2)/(a,2)] (racemate b).
  • A detailed analysis of the development, drug-regulatory approvals, and patents of methylphenidate drugs revealed three double chiral switches: Centedrin, Ritalin, and Focalin.
  • The Food and Drug Administration (FDA) approved Ritalin in 1955, marking the first chiral switch of the mixture of two racemates to the single racemate b.
  • In 2001, Ritalin underwent a second chiral switch to the single-enantiomer Focalin, which has not driven away Ritalin from ADHD markets.
  • The study calls for correct notations of methylphenidate drugs and future applications of the double chiral-switches strategy.
  • The research highlights the stereochemical flaws in the notations of the active ingredients of Ritalin (methylphenidate hydrochloride) and Focalin (dexmethylphenidate hydrochloride).

Statistics:

  • Two chirality centers of methylphenidate hydrochloride give rise to four stereoisomers.
  • The FDA approved Ritalin in 1955.
  • Ritalin underwent a second chiral switch to the single-enantiomer Focalin in 2001.
  • The double chiral-switches strategy has led to the development of successful ADHD treatments such as Ritalin and Focalin.

Sources:

  • Consecutive double chiral-switches strategy. ADHD methylphenidate drugs: from two racemates via racemate to enantiomer. Future Medicinal Chemistry, 2025:1-18.
  • Future Medicinal Chemistry can be contacted at: Taylor & Francis Ltd, 2-4 Park Square, Milton Park, Abingdon OX14 4RN, Oxon, England.
  • Ilaria D'Acquarica, Dipartimento di Chimica e Tecnologie del Farmaco, Sapienza University of Rome, Rome, Italy.
  • Taylor & Francis Ltd, 2-4 Park Square, Milton Park, Abingdon OX14 4RN, Oxon, England.